Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)
Young Suk Kwon, Reena Kudchadker, Neil B. Desai, Raquibul Hannan, MinJae Lee, Ryan Mauck, Jennifer Tse, Kris Gaston, Tamara Dickinson, Shaghayegh Rezaie, Brad Hornberger, Daniel Yang, Maricruz Ibarra, Howard Morgan, Yang Kyun Park, Yesenia Gonzalez, Claus Roehrborn, Robert Timmerman, Solomon Woldu, Aurelie Garant Prostate Cancer and Prostatic Diseases
· Springer Nature
· 2026-11-16
· DOI: 10.1038/s41391-026-01169-6
Abstract
Prostate Cancer and Prostatic Diseases, Published online: 16 November 2026; doi:10.1038/s41391-026-01169-6 Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)
Young Suk Kwon, Reena Kudchadker, Neil B. Desai, Raquibul Hannan, MinJae Lee, Ryan Mauck et al. Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527). // Prostate Cancer and Prostatic Diseases. – 2026. – DOI: 10.1038/s41391-026-01169-6. – URL: https://www.nature.com/articles/s41391-026-01169-6
Young Suk Kwon, Reena Kudchadker, Neil B. Desai, Raquibul Hannan, MinJae Lee, Ryan Mauck, Jennifer Tse, Kris Gaston, Tamara Dickinson, Shaghayegh Rezaie, Brad Hornberger, Daniel Yang, Maricruz Ibarra, Howard Morgan, Yang Kyun Park, Yesenia Gonzalez, Claus Roehrborn, Robert Timmerman, Solomon Woldu, & Aurelie Garant (2026). Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527). Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-026-01169-6
Young Suk Kwon, et al. “Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527).” Prostate Cancer and Prostatic Diseases, 2026. doi:10.1038/s41391-026-01169-6.
@article{Kwon2026,
title = {Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)},
author = {Kwon, Young Suk and Kudchadker, Reena and Desai, Neil B. and Hannan, Raquibul and Lee, MinJae and Mauck, Ryan and Tse, Jennifer and Gaston, Kris and Dickinson, Tamara and Rezaie, Shaghayegh and Hornberger, Brad and Yang, Daniel and Ibarra, Maricruz and Morgan, Howard and Park, Yang Kyun and Gonzalez, Yesenia and Roehrborn, Claus and Timmerman, Robert and Woldu, Solomon and Garant, Aurelie},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2026},
doi = {10.1038/s41391-026-01169-6},
url = {https://www.nature.com/articles/s41391-026-01169-6}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...